Multisensory Rehabilitation for Hemianopia
Trial Summary
What is the purpose of this trial?
This trial aims to help people who are blind in one half of their visual field by using training sessions with matching sights and sounds. The goal is to see if this can help their brains re-learn how to process visual information.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications.
What data supports the effectiveness of the treatment Multisensory Rehabilitation Paradigm, Multisensory Training Paradigm, Visual-Auditory Stimulation Therapy for hemianopia?
Research shows that visual-auditory stimulation therapy can help people with hemianopia (blindness on one side) regain their ability to see in their blind field. In studies, patients who received this therapy were able to detect and describe visual stimuli in their previously blind areas, and improvements were seen quickly and lasted over time.12345
Is multisensory rehabilitation for hemianopia safe for humans?
The studies on multisensory rehabilitation for hemianopia, including visual-auditory stimulation therapy, have shown no reported safety concerns in human participants. The therapy was tested on patients with hemianopia and showed improvements in visual function without any adverse effects mentioned.12356
How is the Multisensory Rehabilitation Paradigm treatment different from other treatments for hemianopia?
The Multisensory Rehabilitation Paradigm is unique because it uses a combination of visual and auditory stimuli to engage the brain's multisensory pathways, which can help restore vision in areas affected by hemianopia. Unlike other treatments that may focus solely on visual exercises, this approach leverages the brain's ability to integrate different sensory inputs, leading to rapid and effective improvements in visual function.12478
Research Team
Benjamin A Rowland, PhD
Principal Investigator
Wake Forest Health Sciences
Eligibility Criteria
This trial is for adults under 85 years old with a stable condition called hemianopia, where half of the visual field is lost. Participants should not have attention deficits related to vision (hemineglect) and must be able to see well enough in their unaffected field to do certain visual tasks.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants engage in weekly multisensory training sessions with visual-auditory stimulation
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Multisensory Rehabilitation Paradigm (Behavioural Intervention)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Wake Forest University Health Sciences
Lead Sponsor
Dr. L. Ebony Boulware
Wake Forest University Health Sciences
Chief Medical Officer since 2022
MD from Duke University School of Medicine, MPH from Johns Hopkins Bloomberg School of Public Health
Dr. Julie Ann Freischlag
Wake Forest University Health Sciences
Chief Executive Officer since 2020
BS from University of Illinois, MD from Rush University
Neuroscience Clinical Trial and Innovation Center (NCTIC)
Collaborator